BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Neomend, Inc's ProGEL Lung Surgery Device Gets FDA Approval


1/19/2010 6:30:28 AM

Bookmark and Share

IRVINE, Calif.--(BUSINESS WIRE)--Neomend, Inc., an innovator in sealant and adhesion-prevention products for the surgical marketplace, announced it has received premarket approval from the U.S. Food and Drug Administration (FDA) for the company’s ProGEL™ Pleural Air Leak Sealant.

ProGEL is a hydrogel polymer sealant consisting of two components: human serum albumin and a cross-linking component of polyethylene glycol. When they are mixed together, a rapid reaction occurs that creates a hydrogel matrix which results in the formation of a strong, adherent and flexible seal.

ProGEL is intended for application to visceral pleura during an open thoracotomy after standard visceral pleural closure with, for example, sutures or staples, of visible air leaks (=2 mm) incurred during open resection of lung parenchyma. ProGELTM Pleural Air Leak Sealant is the only such product with this specific approved indication in the United States.

“We are very excited to receive this approval and be in a position to provide this unique technology to the surgeons and patients who greatly need it,” said David Renzi, the company’s President and CEO. “This technology has also been shown to reduce hospital stay days, a benefit that can significantly reduce the total cost of these procedures to the hospital. Neomend will move quickly to bring this important product to market.”

FDA approval came following a multi-center clinical study on the device that encompassed 161 patients in five institutions: Mayo Clinic, Cedars-Sinai Medical Center, Duke University, MD Anderson Cancer Center, and the University of Washington.

ProGEL was shown to be 77% effective in sealing air leaks intra-operatively, compared to 16% for the control group. The device led to a statistically significant reduction in both intraoperative air leaks and hospital stay of nearly two days.

The newly available device addresses a current, unmet surgical need to seal pleural air leaks incurred during lung surgery. The company estimates approximately 150,000 lung resections are performed in the United States every year. Intraoperative air leaks are a primary complication of lung surgery and can lead to other complications such as infections, pneumonia and extended hospitalization.

Neomend, based in Irvine, Calif., is focused on the design, development and commercialization of surgical sealants and adhesion prevention products derived from the ProGEL technology platform. For more information, visit www.Neomend.com or call 949-916-1630

Contact:

Neomend Wade H. King, MD, 888-PROGEL1 (888-776-4351) Sr. Vice President of Finance doc@Neomend.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES